Sector · Funding
Biotech funding in Europe
Capital tracked€686,406,825
Rounds47
Startups54
Events tracked1
Stories1
Capital tracked
€686.4M
Disclosed rounds
47
Biggest round
€120M
Startups tracked
54
Biotech, in numbers
47 rounds on record · 47 with a disclosed amount
Rounds by stage
Rounds by stage. Donut chart, 6 slices. Series A 14 (37%), Seed 11 (29%), Pre-seed 8 (21%), Series B 2 (5%), Series C 1 (3%), Other (2) 2 (5%).
- Series A1437%
- Seed1129%
- Pre-seed821%
- Series B25%
- Series C13%
- Other (2)25%
Source: Sesamers round tracker
Capital by year
Capital by year. Bar chart, 4 bars. Highest: 2026, €356.5M. Lowest: 2024, €15M. Values: 2023 €15.5M, 2024 €15M, 2025 €215.3M, 2026 €356.5M.
Source: Sesamers round tracker
Share of rounds
Share of rounds by stage. Bar chart, 7 rows. Series A 37%, Seed 29%, Pre-seed 21%, Series B 5%, Series C 3%, Series D+ 3%, Grant 2%.
Source: Sesamers round tracker
n = 47 rounds
Largest rounds tracked
Disclosed rounds only · EUR-converted at desk rates
| Company | Round | Sector | Lead | Amount |
|---|---|---|---|---|
| Basecamp Research United Kingdom | Series C | AI | S32 | €120M |
| Artios United Kingdom | Series D+ | Biotech | SV Health Investors, RA Capital Management | €105.8M |
| IMU Biosciences United Kingdom | Series A | Biotech | IQ Capital, Molten Ventures | €45.6M |
| Bioptimus France | Series A | AI | Cathay Innovation | €39.8M |
| Aerska Ireland | Series A | Biotech | EQT Dementia Fund, age1 | €32M |
| Standing Ovation France | Series B | Alternative Protein | Ecotechnologies 2 (Bpifrance), Crédit Mutuel Innovation | €30M |
What we have written
1 story on Biotech
05Apr Generare raises €20 million to unlock novel molecules from microbial genomes Europe’s biotechnology sector is experiencing a significant structural shift in how the pharmaceutical industry approaches early-stage…
Startups in Biotech
From the directory
BR
Basecamp Research
AI
London biotech training EDEN biological foundation models on a 30-country biodiversity data network to design new therapeutics, including…
Series C · €120,000,000
view →
BP
Big Picture Bio
Biotech · Pre-seed
Uses multi-agent AI to predict novel synergistic drug combinations beyond the reach of foundation models and traditional machine…
Pre-seed · €1,750,000
view →
Eterna Regeneratives
Biotech · Seed
Eterna Regeneratives develops keratin-based biomaterials, sourced from human hair and sheep's wool, that repair tooth enamel through biomimetic…
Seed · €3,500,000
view →
Who invests here
Funds with a verified round in this hub · most active first
Seventure Partners
Growth–Seed · Biotech
Led 4 of 5 rounds tracked in Biotech. Founded in 1997 and backed by Natixis Investment Managers, Seventure Partners is…
view →
Elaia Partners
Pre-seed–Seed · AI
Led 2 of 2 rounds tracked in Biotech. Elaia is a European venture capital firm with roughly 850 million euros…
view →
Omnes Capital
Growth–Series A · AI
Led 1 of 2 rounds tracked in Biotech. Omnes Capital is a French private-assets manager founded in 1999 as Credit…
EUR 5M–EUR 7M
view →
Next up
The Biotech calendar · 1 tracked
09Nov CPHI Frankfurt 2027 Tradeshow · Frankfurt, Germany 3 days
Programs in Biotech
Open calls first
DA
DayOne Accelerator – 2027
Accelerator
CHF 1,000 travel grant; DayOne NEXT gives up to 3 startups CHF 50,000 non-dilutive post-programme · None
Upcoming
view →
EB
Eureka Biotech Call – September 2026
Grant
Grant or loan, up to 70% of project costs depending on country · None
Closed
view →
Life Sciences Baltics – Startup Pitch Battle 2025
Competition
Twenty startups are selected, ten pitching on each day of the conference in front of investors, industry experts and decision-makers. The battle puts winners in front of LitBAN, HealthSeed Venture Studio, imago venture studio and BSV Ventures for investment, and offers a one-week intensive programme in Akron, Ohio meeting universities and venture capitalists, plus fast-track access to LitBAN's monthly pitch event, mentorship, acceleration support and advisory. No cash prize is published. · None taken by the organisers; the named funds and venture studios invest on their own terms.
Closed
view →